




PHARMACEUTICAL 2018

Savara Inc
Rank 89 of 342





PHARMACEUTICAL 2018

Savara Inc
Rank 89 of 342



The relative strengths and weaknesses of Savara Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Savara Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 42% points. The greatest weakness of Savara Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 67% points.

The company's Economic Capital Ratio, given in the ranking table, is 176%, being 131% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	97,864
Cost of Goods Sold	0
Intangible Assets	27,082
Liabilities, Current	6,015
Liabilities, Non-Current	0
Other Assets	33,757
Other Compr. Net Income	1,549
Other Expenses	-3,271
Other Liabilities	34,304
Other Net Income	-3,475
Other Revenues	0
Property and Equipment	925
Research and Development	18,512
Selling, General and Administrative Expense	11,081

Output Variable	Value in 1000 USD
Assets	159,628
Liabilities	40,319
Expenses	26,322
Revenues	0
Stockholders Equity	119,309
Net Income	-29,797
Comprehensive Net Income	-29,022
Economic Capital Ratio	176%